Phase Ib/II study of ALT-801 with cisplatin in patients with metastatic melanoma
Stopped early
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 combined with cisplatin. The purpose of this study is to evaluate the safety, determine the Maximum-Tolerated Dose (MTD), and characterize the pharmacokinetic profile of A…
Phase 1/2 • Sponsor: Altor BioScience
Last updated Sep 10, 2026 15:00 UTC